Agios Pharmaceuticals (NASDAQ:AGIO) Given New $62.00 Price Target at HC Wainwright

Posted by Geri Gentry on Nov 7th, 2026

Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) had its price objective boosted by HC Wainwright from $55.00 to $62.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

A number of other analysts have also recently commented on the company. Bank of America upped their price objective on Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Citigroup increased their target price on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 31st. JPMorgan Chase & Co. raised their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Truist Financial cut their price target on Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating for the company in a research note on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $42.12.

Read Our Latest Research Report on Agios Pharmaceuticals

Agios Pharmaceuticals Stock Up 4.0%

AGIO traded up $1.14 during mid-day trading on Friday, reaching $29.41. 1,281,176 shares of the company traded hands, compared to its average volume of 1,338,915. The stock has a market capitalization of $1.76 billion, a P/E ratio of -4.65 and a beta of 0.66. The company’s fifty day moving average price is $33.27 and its 200-day moving average price is $31.76. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.15. The firm had revenue of $55.39 million for the quarter, compared to the consensus estimate of $51.65 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. As a group, sell-side analysts forecast that Agios Pharmaceuticals will post -5.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of the stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $37.69, for a total value of $296,469.54. Following the transaction, the insider directly owned 54,645 shares in the company, valued at approximately $2,059,570.05. This trade represents a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 9,855 shares of company stock valued at $371,112 in the last 90 days. 5.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. raised its holdings in Agios Pharmaceuticals by 73.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 115,848 shares of the biopharmaceutical company’s stock worth $3,852,000 after purchasing an additional 48,992 shares during the period. Three Bridge Wealth Advisors LLC purchased a new position in Agios Pharmaceuticals during the third quarter valued at $27,000. Jefferies Financial Group Inc. purchased a new position in Agios Pharmaceuticals during the third quarter valued at $1,020,000. Lido Advisors LLC bought a new stake in Agios Pharmaceuticals during the third quarter valued at about $411,000. Finally, Fulcrum Asset Management LLP bought a new stake in Agios Pharmaceuticals during the third quarter valued at about $94,000.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

Positive Sentiment: Q3 results beat expectations: Agios reported a loss of $1.09 per share, narrower than analyst estimates, while revenue of $55.39 million topped the $51.65 million consensus. The per-share loss also improved from $1.78 a year earlier. Agios Q3 results and business update
Positive Sentiment: Mitapivat growth and regulatory milestone: Mitapivat revenue increased more than fourfold, and an FDA decision on the drug for sickle-cell disease is expected in February 2027. Strong sales and a potential approval could support future growth, though the FDA outcome remains uncertain. Mitapivat revenue and FDA timeline
Positive Sentiment: HC Wainwright raised its target: The firm lifted its price target from $55 to $62 and maintained a Buy rating, signaling substantial expected upside from the cited share price. HC Wainwright recommendations
Neutral Sentiment: Truist lowered its target but kept a Buy rating: Truist cut its target from $37 to $35, while continuing to see upside from the cited price. The reduction tempers, but does not reverse, its positive stance. Truist recommendations
Negative Sentiment: Planned R&D workforce reductions: Agios aims to eliminate more than 100 R&D roles. Cuts could reduce costs, but may also raise concerns about research capacity and execution as the company approaches a key regulatory decision. Agios R&D job cuts

Agios Pharmaceuticals Company Profile

(Get Free Report)

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.